Efficacy and Safety of Low-Dose Valganciclovir for Prevention of Cytomegalovirus Disease in Renal Transplant Recipients: A Single-Center, Retrospective Analysis-Reference-Cited by-同舟云学术

Efficacy and Safety of Low-Dose Valganciclovir for Prevention of Cytomegalovirus Disease in Renal Transplant Recipients: A Single-Center, Retrospective Analysis

Published:2004-10 Issue:10 Volume:24 Page:1323-1330
ISSN:0277-0008
Container-title:Pharmacotherapy
language:en
Short-container-title:Pharmacotherapy

Author:

Gabardi Steven,Magee Colm C.,Baroletti Steven A.,Powelson John A.,Cina Jennifer L.,Chandraker Anil K.

Publisher

Wiley

Subject

Pharmacology (medical)

Reference27 articles.

1. Definitions of Cytomegalovirus Infection and Disease in Transplant Recipients

2. Infection in Organ-Transplant Recipients

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Challenges for the improvement of valganciclovir prophylaxis in solid organ transplantation and the possible role of therapeutic drug monitoring in adults;British Journal of Clinical Pharmacology;2024-06-18

2. Low-Dose vs Standard-Dose Valganciclovir for Cytomegalovirus Prophylaxis After Kidney Transplantation: A Single-Center Retrospective Analysis;Transplantation Proceedings;2024-01

3. Real world experience with conversion from valganciclovir to letermovir for cytomegalovirus prophylaxis: Letermovir reverses leukopenia and avoids mycophenolate dose reduction;Clinical Transplantation;2023-09-27

4. Burden of neutropenia and leukopenia among adult kidney transplant recipients: A systematic literature review of observational studies;Transplant Infectious Disease;2023-01-19

5. Management of drug‐induced neutropenia, thrombocytopenia, and anaemia after solid organ transplantation: A comprehensive review;Journal of Clinical Pharmacy and Therapeutics;2022-10-17